健民集团：获得《药物临床试验批准通知书》

Core Viewpoint - Jianmin Group (600976) has received the Clinical Trial Approval Notice for Yimufuyin Granules from the National Medical Products Administration [1] Group 1 - Jianmin Group announced the receipt of the approval notice on the evening of October 27 [1]